Category: Endocrinology

In 2021, approximately 537 million adults worldwide were living with diabetes, a condition closely linked to insulin resistance. When asking 'Is semaglutide or tirzepatide better for insulin resistance?', clinical evidence points towards a clear frontrunner.

Over 88 million American adults have prediabetes, a condition often driven by insulin resistance. While Ozempic (semaglutide) has gained significant attention for its effectiveness in managing type 2 diabetes and promoting weight loss, it is not approved or recommended as a first-line treatment for insulin resistance alone. This article explains the clinical guidelines, safety concerns, and ethical considerations behind this prescribing decision.

Insulin resistance affects a significant portion of the population, often preceding prediabetes and type 2 diabetes. For those seeking pharmacological support, the question, 'What is the drug of choice for insulin resistance?', often arises, with metformin being the most common first-line option.

The first reports linking lipodystrophy to antiretroviral therapy (ART) in HIV-positive individuals emerged in 1997. This condition, which alters how the body stores and uses fat, can be a challenging side effect for patients, significantly impacting both their physical appearance and metabolic health. Understanding **which drugs cause lipodystrophy** is crucial for both healthcare providers and patients to manage and mitigate its effects.

Hyponatremia is the most common electrolyte disorder found in clinical practice, affecting 15-30% of hospitalized patients [1.3.6, 1.6.6]. This article explores the question: how do corticosteroids cause hyponatremia through their complex influence on hormones and kidney function.

Mounjaro (tirzepatide) is an FDA-approved prescription medication specifically designed to help improve blood sugar control in adults with type 2 diabetes. The misconception, 'Can Mounjaro cause diabetes?', is frequently asked, but the medical evidence shows the drug is a powerful treatment, not a cause, of the disease.

Certain foods, supplements, and medications can significantly interfere with levothyroxine absorption, with some substances reducing its effectiveness by binding to the hormone [1.2.5, 1.3.2]. Understanding what cannot be taken with levothyroxine is crucial for maintaining stable thyroid hormone levels and overall health [1.2.5].

Over 70% of patients receiving the intravenous iron formulation ferric carboxymaltose (FCM) experience hypophosphatemia, or low phosphate, within weeks of treatment. The answer to "do iron infusions cause low phosphate?" is yes, but the risk varies significantly depending on the specific product used. This emerging safety concern is mediated by a complex hormonal pathway involving FGF23.

Drug-induced hyperprolactinemia is the most common cause of consistently high prolactin levels, with its incidence tripling over a recent 20-year period [1.9.1]. But the question remains for many patients: do beta blockers increase prolactin levels as part of this trend?

In children with Growth Hormone Deficiency, the first year of GH therapy can result in a growth increase of two to three times faster than before treatment, a phenomenon known as 'catch-up' growth [1.2.4]. Knowing how to tell if growth hormone is working involves tracking both clinical data and subjective patient-reported outcomes.